Memorial Sloan Kettering Cancer Center: “Lung Cancer Genomic Testing (EGFR, KRAS, ALK).” National Cancer Institute: “Targeted Therapy to Treat Cancer.” CDC: “How Is Lung Cancer Diagnosed ...

Colorectal cancer has moved into the era of personalized medicine, and future advances are likely to refine the biomarkers used to select anti-EGFR treatment for KRAS wild-type mCRC. Novel drug ...

Accordingly, the researchers next plan to investigate the extent to which individual KRAS mutations influence response to EGFR inhibitors, such as cetuximab. “Future personalized patient ...

The majority of people with advanced EGFR-mutant non-small cell lung cancer (NSCLC) receiving first-line osimertinib ...

Learn about research at MSK that finds obesity can influence driver mutations that produce specific subtypes of cancers, ...

And, in non-small cell lung cancer with specific EGFR mutations, MI Cancer Seek can be used with approved tyrosine kinase ...

SOS1 is a guanine nucleotide exchange factor (GEF) that activates KRAS, and recent preclinical studies have demonstrated that combining KRAS and EGFR inhibitors with SOS1 inhibitors can overcome ...

Memorial Sloan Kettering Cancer Center: “Lung Cancer Genomic Testing (EGFR, KRAS, ALK).” National Cancer Institute: “Understanding laboratory tests.” Late-Stage NSCLC: What your doctor may ...

Cardiff has a cash runway of 5-6 quarters, but will need additional funding, potentially leading to significant shareholder ...

The company’s pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs (CNS-penetrant KRAS G12C and EGFR inhibitors), and seven discovery-stage programs ...

The company’s pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs (CNS-penetrant KRAS G12C and EGFR inhibitors), and seven discovery-stage programs ...

[2] Good evidence exists for the use of anti-EGF receptor (EGFR) monoclonal antibody treatment as part of first-line combination chemotherapy including infusional 5-fluorouracil and for third-line ...